What is it about?
Polysialic acid (polySia) is a distinctive glycan involved in various important biological processes. However, existing tools for polySia analysis face various limitations, making its precise detection and characterization challenging. To address these challenges, we developed an artificial recognition material or a molecularly imprinted polymer, termed a “glycan superbinder”, that recognizes polySia with greater affinity and selectivity than a benchmark monoclonal antibody. Using this material, we revealed increased levels of polysialylated CD56 (polySia-CD56) in pancreatic cancer tissues and demonstrated its potential as a blood-based diagnostic biomarker. Notably, polySia-CD56 shows promise for identifying pancreatic cancer in CA19-9-negative patients, while its combination with CA19-9 further improves diagnostic accuracy.
Featured Image
Photo by Terry Vlisidis on Unsplash
Why is it important?
CA19-9 is a widely used biomarker for pancreatic cancer, but its diagnostic performance remains limited, and some patients with pancreatic cancer may test negative for CA19-9. This highlights the need for more precise and complementary biomarkers that can help identify patients who might otherwise be missed. Our findings reveal increased levels of polySia-CD56 in pancreatic cancer tissues, providing new evidence for the association between polySia and pancreatic cancer. More importantly, in our clinical evaluation, polySia-CD56 shows superior diagnostic performance compared with CA19-9. Notably, it offers a promising approach to identifying pancreatic cancer in patients who test negative for CA19-9, potentially helping to reduce missed diagnoses. Furthermore, the two biomarkers provide complementary diagnostic information, and their combination further improves diagnostic accuracy. These findings suggest that polySia-CD56 could help overcome important limitations of CA19-9 and improve existing diagnostic strategies for pancreatic cancer. Beyond pancreatic cancer diagnosis, this study highlights the valuable biological and diagnostic information carried by glycans attached to specific proteins and underscores the critical role of molecularly imprinted glycan superbinders in revealing this information and advancing biomedical research and disease diagnosis.
Perspectives
We believe that important diagnostic information may be hidden not only in the abundance of proteins but also in the glycan chains attached to them. Developing more glycan superbinders with high affinity and specificity could help uncover disease-associated molecular signatures that are difficult to detect using conventional approaches and advance our understanding of glycan biology. Future studies focusing on the underlying molecular mechanisms, the development of high-throughput and precise detection methods, and validation in larger, more diverse patient cohorts will be important for further evaluating the clinical potential of polySia-CD56.
Zhen Liu
Nanjing University
Read the Original
This page is a summary of: A glycan superbinder reveals polysialylated-CD56 as a precision biomarker for pancreatic cancer, Proceedings of the National Academy of Sciences, October 2026, Proceedings of the National Academy of Sciences,
DOI: 10.1073/pnas.2611747123.
You can read the full text:
Resources
Contributors
The following have contributed to this page
